An upcoming Supreme Court ruling could extend product royalties beyond the life of a patent, and thus have a major impact on pharma and medtech deal structures and bottom lines. This article covers what companies need to do now to prepare.
5.13.2015
McCarter & English, LLP | Contents of this website may contain attorney advertising. | Results may vary depending on your particular facts and legal circumstances.
Browse Alphabetically:
Publications|Article
The Patent Is Dead; Long Live The Royalties!
Pharma & Medtech Business IntelligenceThe McCarter & English, LLP website is for informational purposes only. We do not provide legal advice on this website. We can provide legal advice only to our clients in specific inquiries that they address to us. If you are interested in becoming a client, please contact us, but do not send any information about your specific legal question. We cannot serve as your lawyers until we establish an attorney-client relationship, which can occur only after we follow procedures within our firm and after we agree to the terms of the representation.
Accept Cancel